Prevalence, diagnosis, and treatment of migraine due to iron deficiency

Prevalence, diagnosis, and treatment of migraine due to iron deficiency - Prevalence, diagnosis, and treatment of migraine due to iron deficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058501

Enrollment

631

Registered

2025-10-01

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who visited a participating facility for outpatient treatment with migraine between April 1, 2022 and May 22, 2025.

Exclusion criteria

Exclusion criteria: Patients with vertebral artery dissection, brain tumor, or other vascular disorders were excluded. Patients with insufficient data on iron-related parameters were excluded.

Design outcomes

Primary

Measure	Time frame
Prevalence of iron deficiency in migraine patients (assessed based on hemoglobin [Hb], serum iron [Fe], total iron-binding capacity [TIBC], transferrin saturation [TSAT: calculated as Fe/TIBC], and serum ferritin)	—

Secondary

Measure	Time frame
Clinical usefulness of iron supplementation therapy (improvement in MHD, HIT-6, and MIBS-4), and efficacy of iron monotherapy during pregnancy and lactation	—

Countries

Japan

Contacts

Public ContactEiichi Suehiro

International University of Health and Welfare Narita Hospital Neurosurgery

esuehiro@iuhw.ac.jp0476355600

Outcome results